06 / The sources
BPC-157 TB-500: references and primary sources.
Every quantitative claim on this site maps to a numbered entry below. Component peptide studies carry PubMed and DOI links; the regulatory facts carry their FDA source pages.
How to read this list
The references below are the full source set for the BPC-157 TB-500 digest. Entries 1-11 are peer-reviewed studies and reviews on the two component peptides; entries 12-14 are the FDA regulatory sources behind the legal-status page. Each peptide study links to its PubMed record and DOI; each regulatory entry links to the FDA page that supports the cited fact.
Two framing notes carry across the list. First, the component evidence is overwhelmingly preclinical, and no entry describes a controlled trial of the assembled blend. Second, the human safety data filed under "TB-500" are for full-length Thymosin Beta-4, not the Ac-LKKTETQ heptapeptide — a distinction the relevant entries make explicit.
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
- Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. ↗
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. ↗
- Wang Y, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
- Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. ↗
- A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021. ↗
- Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. ↗
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 entries for BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; list entries effective September 29, 2023). ↗
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (public calendar listing BPC-157 and TB-500 among bulk drug substances 'being considered for inclusion on the 503A Bulks List'). ↗
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (503A/503B framework, bulks-list eligibility, and Category 1/Category 2 interim policy). ↗